Your browser doesn't support javascript.
loading
Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
Hosono, Naoko; Makishima, Hideki; Mahfouz, Reda; Przychodzen, Bartlomiej; Yoshida, Kenichi; Jerez, Andres; LaFramboise, Thomas; Polprasert, Chantana; Clemente, Michael J; Shiraishi, Yuichi; Chiba, Kenichi; Tanaka, Hiroko; Miyano, Satoru; Sanada, Masashi; Cui, Edward; Verma, Amit K; McDevitt, Michael A; List, Alan F; Saunthararajah, Yogen; Sekeres, Mikkael A; Boultwood, Jacqueline; Ogawa, Seishi; Maciejewski, Jaroslaw P.
Afiliação
  • Hosono N; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Makishima H; First Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
  • Mahfouz R; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Przychodzen B; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Yoshida K; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Jerez A; Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • LaFramboise T; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Polprasert C; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Clemente MJ; Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.
  • Shiraishi Y; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Chiba K; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Tanaka H; Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Miyano S; Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Sanada M; Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Cui E; Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Verma AK; Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • McDevitt MA; Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • List AF; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Saunthararajah Y; Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.
  • Sekeres MA; Department of Oncology, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Boultwood J; Division of Hematology and Hematological Malignancy, Department of Internal Medicine and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Ogawa S; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Maciejewski JP; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Oncotarget ; 8(4): 6483-6495, 2017 Jan 24.
Article em En | MEDLINE | ID: mdl-28031539
ABSTRACT

BACKGROUND:

Deletion of chromosome 5q (del(5q)) is the most common karyotypic abnormality in myeloid neoplasms. MATERIALS AND

METHODS:

To define the pathogenic molecular features associated with del(5q), next-generation sequencing was applied to 133 patients with myeloid neoplasms (MDS; N = 69, MDS/MPN; N = 5, sAML; N = 29, pAML; N = 30) with del(5q) as a sole abnormally or a part of complex karyotype and results were compared to molecular features of patients diploid for chr5.

FINDINGS:

A number of 5q genes with haploinsufficient expression and/or recurrent somatic mutations were identified; for these genes, CSNK1A1 and G3BP1 within the commonly deleted 5q region and DDX41 within a commonly retained region were most commonly affected by somatic mutations. These genes showed consistent haploinsufficiency in deleted cases; low expression/mutations of G3BP1 or DDX41 were associated with poor survival, likely due to decreased cellular function. The most common mutations on other chromosomes in patients with del(5q) included TP53, and mutations of FLT3 (ITD or TKD), NPM1 or TET2 and were mutually exclusive. Serial sequencing allowed for definition of clonal architecture and dynamics, in patients with exome sequencing allelic imbalance for informative SNPs facilitated simultaneous approximation of clonal size of del(5q) and clonal burden for somatic mutations.

INTERPRETATION:

Our results illuminate the spectrum of molecular defects characteristic of del(5q), their clinical impact and succession of stepwise evolution.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Biomarcadores Tumorais / Anemia Macrocítica / Transtornos Mieloproliferativos Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Biomarcadores Tumorais / Anemia Macrocítica / Transtornos Mieloproliferativos Idioma: En Ano de publicação: 2017 Tipo de documento: Article